Abordaje del paciente con colestasis y síndrome ictérico. Posicionamiento científico conjunto AMH, AMG, AMEG

Trauner, 1998, Molecular pathogenesis of cholestasis, New Engl J Med., 339, 1217, 10.1056/NEJM199810223391707 Beuers, 2015, New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR PXR and beyond, J Hepatol., 62, S25, 10.1016/j.jhep.2015.02.023 Huang, 2017, Evolution in the utilization of biliary interventions in the United States: Results of a nationwide longitudinal study from 1998 to 2103, Gastrointest Endosc., 86, 319, 10.1016/j.gie.2016.12.021 Rösch, 2002, A prospective comparison of the diagnostic accuracy of ERCP, MRCP CT, and EUS in biliary strictures, Gastrointest Endosc., 55, 870, 10.1067/mge.2002.124206 Park, 2004, Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: Findings at MRCP versus ERCP, Radiology., 233, 234, 10.1148/radiol.2331031446 Kalaitzakis, 2012, Endoscopic diagnosis of biliary tract disease, Curr Opin Gastroenterol., 28, 273, 10.1097/MOG.0b013e328351436e Rösch, 2004, ERCP or EUS for tissue diagnosis of biliary strictures? A prospective comparative study, Gastrointest Endosc., 60, 390, 10.1016/S0016-5107(04)01732-8 Rizvi, 2013, Pathogenesis, diagnosis, and management of cholangiocarcinoma, Gastroenterology., 145, 1215, 10.1053/j.gastro.2013.10.013 Chen, 2011, Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos), Gastrointest Endosc., 74, 805, 10.1016/j.gie.2011.04.016 Hildebrand, 2016, Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis, Liver Transpl., 22, 42, 10.1002/lt.24350 Vitale, 2008, Endoscopic management of postcholecystectomy bile duct strictures, J Am Coll Surg., 206, 918, 10.1016/j.jamcollsurg.2008.01.064 Kwo, 2017, ACG clinical guideline: Evaluation of abnormal liver chemistries, Am J Gastroenterol., 112, 18, 10.1038/ajg.2016.517 Newsome, 2018, Guidelines on the management of abnormal liver blood tests, Gut., 67, 6, 10.1136/gutjnl-2017-314924 Coates, 2011, Liver function tests, Aust Fam Physician., 40, 113 Lucey, 2009, Alcoholic hepatitis, N Engl J Med., 360, 2758, 10.1056/NEJMra0805786 Benichou, 1993, Causality assessment of adverse reactions to drugs — II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge, J Clin Epidemiol., 46, 1331, 10.1016/0895-4356(93)90102-7 Srivastava, 2014, Progressive familial intrahepatic cholestasis, J Clin Exp Hepatol., 4, 25, 10.1016/j.jceh.2013.10.005 Fargo, 2017, Evaluation of jaundice in adults, Am Fam Physician., 95, 164 Lindor, 2009, Primary biliary cirrhosis, Hepatology., 50, 291, 10.1002/hep.22906 Lindor, 2019, Primary biliary cholangitis: 2018 Practice guidance from the American Association for the Study of Liver Diseases, Hepatology., 69, 394, 10.1002/hep.30145 Kouroumalis, 2018, Biomarkers for primary biliary cholangitis: Current perspectives, Hepat Med., 10, 43, 10.2147/HMER.S135337 Romero-Gómez, 1999, Anti-Sp100 and anti-Gp210 in the diagnosis of primary biliary cirrhosis in patients with autoimmune cholangitis, Gastroenterol Hepatol., 22, 11 Bunchorntavakul, 2015, Diagnosis and management of overlap syndromes, Clin Liver Dis., 19, 81, 10.1016/j.cld.2014.09.005 Lazaridis, 2016, Primary sclerosing cholangitis, N Engl J Med., 375, 1161, 10.1056/NEJMra1506330 Kaplan, 2007, The burden of large and small duct primary sclerosing cholangitis in adults and children: A population-based analysis, Am J Gastroenterol., 102, 1042, 10.1111/j.1572-0241.2007.01103.x Czaja, 2014, Overlap syndromes, Clin Liver Dis, 3, 2, 10.1002/cld.294 Sundaram, 2017, Drug-induced cholestasis, Hepatol Commun., 1, 726, 10.1002/hep4.1088 DeLeve, 1995, Mechanisms of drug-induced liver disease, Gastroenterol Clin North Am., 24, 787, 10.1016/S0889-8553(21)00228-4 Chalasani, 2014, ACG clinical guideline: The diagnosis and management of idiosyncratic drug-induced liver injury, Am J Gastroenterol., 109, 950, 10.1038/ajg.2014.131 Rochon, 2008, Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury, Hepatology., 48, 1175, 10.1002/hep.22442 Hoofnagle, 2019, Drug-induced liver injury — types and phenotypes, N Engl J Med., 381, 264, 10.1056/NEJMra1816149 Bjornsson, 2016, Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports, Hepatology., 63, 590, 10.1002/hep.28323 Williamson, 2014, Intrahepatic cholestasis of pregnancy, Obstet Gynecol., 124, 120, 10.1097/AOG.0000000000000346 Gomes, 2018, Gastrointestinal diseases during pregnancy: What does the gastroenterologist need to know?, Ann Gastroenterol., 31, 385 Benjaminov, 2004, Liver disease in pregnancy, Am J Gastroenterol., 99, 2479, 10.1111/j.1572-0241.2004.30231.x Beuers, 2009, EASL clinical practice guidelines: Management of cholestatic liver diseases, J Hepatol., 51, 237, 10.1016/j.jhep.2009.04.009 Gossard, 2013, Care of the cholestatic patient, Clin Liver Dis., 17, 331, 10.1016/j.cld.2012.11.005 Arab, 2017, Bile acids in cholestasis and its treatment, Ann Hepatol., 16, s53, 10.5604/01.3001.0010.5497 Cabrera, 2019, UDCA NorUDCA, and TUDCA in liver diseases: A review of their mechanisms of action and clinical applications, Handb Exp Pharmacol., 256, 237, 10.1007/164_2019_241 Shoda, 1927, Über die ursodesoxycholsäure aus barengallen und ihre physiologische wirking, K Biochem., 7, 505 Lindor, 2019, Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver diseases, Hepatology., 69, 394, 10.1002/hep.30145 Mitsuyoshi, 1999, Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants, Biochem Biophys Res Commun., 263, 537, 10.1006/bbrc.1999.1403 Ward, 2017, Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon, Am J Physiol Gastrointest Liver Physiol., 312, G550, 10.1152/ajpgi.00256.2016 Goldstein, 2018, Novel and emerging therapies for cholestatic liver diseases, Liver Int., 38, 1520, 10.1111/liv.13880 Lindström, 2013, Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis, Clin Gastroenterol Hepatol., 11, 841, 10.1016/j.cgh.2012.12.032 Lindor, 2015, ACG clinical guideline: Primary sclerosing cholangitis, Am J Gastroenterol., 110, 646, 10.1038/ajg.2015.112 Lammers, 2014, Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study, Gastroenterology., 147, 1338, 10.1053/j.gastro.2014.08.029 2017, EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis, J Hepatol., 67, 145, 10.1016/j.jhep.2017.03.022 Nevens, 2016, A placebo-controlled trial of obeticholic acid in primary biliary cholangitis, N Engl J Med., 375, 631, 10.1056/NEJMoa1509840 Hirschfield, 2018, The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines, Gut., 67, 1568, 10.1136/gutjnl-2017-315259 Hegade, 2016, Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score, Dig Dis Sci., 61, 3037, 10.1007/s10620-016-4250-y Cheung, 2016, Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes, Aliment Pharmacol Ther., 43, 283, 10.1111/apt.13465 Coperchot, 2018, A placebo-controlled trial of bezafibrate in primary biliary cholangitis, N Engl J Med., 378, 2171, 10.1056/NEJMoa1714519 Hirschfield, 2021, A placebo-controlled randomized trial of budesonide for PBC following an insufficient response to UDCA, J Hepatol., 74, 321, 10.1016/j.jhep.2020.09.011 Silveira, 2014, Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis, Expert Opin Pharmacother., 15, 365, 10.1517/14656566.2014.873404 Gong, 2005, Colchicine for primary biliary cirrhosis: A Cochrane Hepato-biliary Group systematic review of randomized clinical trials, Am J Gastroenterol., 100, 1876, 10.1111/j.1572-0241.2005.41522.x Gupta, 1982, Isolation of antihepatotoxic agents from seeds of Silybum marianum, Res Ind., 27, 37 Schuppan, 1999, Herbal products for liver diseases: A therapeutic challenge for the new millennium, Hepatology., 30, 1099, 10.1002/hep.510300437 Ramellini, 1974, Stabilization of isolated rat liver plasma membranes by treatment in vitro with silymarin, Arzneimittelforschung., 24, 806 Farghali, 2000, Silymarin effects on intracellular calcium and cytotoxicity: A study in perfused rat hepatocytes after oxidative stress injury, Pharmacol Res., 41, 231, 10.1006/phrs.1999.0575 Dehmlow, 1996, Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin, Hepatology., 23, 749, 10.1002/hep.510230415 Machicao, 1977, Mechanism of the stimulation of RNA synthesis in rat liver nuclei by silybin, Hoppe Seylers Z Physiol Chem., 358, 141, 10.1515/bchm2.1977.358.1.141 Walker, 2020, Pharmacological interventions for treating intrahepatic cholestasis of pregnancy, Cochrane Database Syst Rev., 7 Crocenzi, 2000, Effect of silymarin on biliary bile salt secretion in the rat, Biochem Pharmacol., 59, 1015, 10.1016/S0006-2952(99)00407-4 Muriel, 2003, Fibrosis and glycogen stores depletion induced by prolonged biliary obstruction in the rat are ameliorated by metadoxine, Liver Int., 23, 262, 10.1034/j.1600-0676.2003.00837.x Khanna, 2018, Symptoms of PBC — Pathophysiology and management, Best Pract Res Clin Gastroenterol., 34-35, 41, 10.1016/j.bpg.2018.06.007 De Vries, 2021, Fibrates for itch (FITCH) in fibrosing cholangiopathies: A double-blind, randomized, placebo-controlled trial, Gastroenterology., 160, 734, 10.1053/j.gastro.2020.10.001 Anthero de Azevedo, 2017, Pruritus in cholestasis, Rev Soc Bras Clin Med., 15, 61 Shah, 2021, Cholestatic jaundice, StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. 2021 Jul 17 Lee, 2019, Treatment of fatigue in primary biliary cholangitis: A systematic review and meta-analysis, Dig Disc Sci., 64, 2338, 10.1007/s10620-019-5457-5 Silveira, 2017, A randomized, placebo-controlled clinical trial of efficacy and safety: Modafinil in the treatment of fatigue in patients with primary biliary cirrhosis, Am J Ther., 24, e167, 10.1097/MJT.0000000000000387 Jones, 2007, An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis, Aliment Pharmacol Ther., 25, 471, 10.1111/j.1365-2036.2006.03223.x Glasova, 2002, Extrahepatic manifestations of cholestasis, J Gastroenterol Hepatol., 17, 938, 10.1046/j.1440-1746.2002.02717.x Assis, 2018, Chronic complications of cholestasis: Evaluation and management, Clin Liver Dis., 22, 533, 10.1016/j.cld.2018.03.014 Frith, 2011, Autonomic dysfunction in chronic liver disease, Hepat Med., 3, 81 Shaheen, 2018, The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes, PLoS One., 13, 10.1371/journal.pone.0194839 Guañabens, 2010, Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis, Gastroenterology., 138, 2348, 10.1053/j.gastro.2010.02.016 Gasser, 2008, Cholestasis and metabolic bone disease — a clinical review, Wien Med Woschenschr., 158, 553, 10.1007/s10354-008-0594-z Zein, 2005, Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo-controlled trial, Hepatology., 42, 762, 10.1002/hep.20866 Alnounou, 2006, Nutrition concerns of the patient with primary biliary cirrhosis or primary sclerosing cholangitis, Pract Gastroenterol., 30, 92 Sampaziotis, 2012, Severe coagulopathy caused by rifampicin in patients with primary sclerosing cholangitis and refractory pruritus, Br J Clin Pharmacol., 73, 826, 10.1111/j.1365-2125.2011.04158.x Schiff, 2007 Westbrook, 2016, Pregnancy and liver disease, J Hepatol., 64, 933, 10.1016/j.jhep.2015.11.030 Tran, 2016, ACG clinical guideline: Liver disease and pregnancy, Am J Gastroenterol., 111, 176, 10.1038/ajg.2015.430 Geenes, 2009, Intrahepatic cholestasis of pregnancy, World J Gastroenterol., 15, 2049, 10.3748/wjg.15.2049 Goel, 2014, Pregnancy-related liver disorders, J Clin Exp Hepatol., 4, 151, 10.1016/j.jceh.2013.03.220 Beuers, 2015, New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR PXR and beyond, J Hepatol., 62, S25, 10.1016/j.jhep.2015.02.023 Geenes, 2015, Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy, Eur J Obstet Gynecol Reprod Biol., 189, 59, 10.1016/j.ejogrb.2015.03.020 Diac, 2006, Dexamethasone in the treatment of obstetric cholestasis: A case series, J Obstet Gyneacol., 26, 110, 10.1080/01443610500443246 Pan, 2011, Pregnancy-related liver diseases, Clin Liver Dis., 15, 199, 10.1016/j.cld.2010.09.007 Sebiha, 2015, Review of a challenging clinical issue: Intrahepatic cholestasis of pregnancy, World J Gastroenterol, 21, 7134, 10.3748/wjg.v21.i23.7134 Anstee, 2012, S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility, J Hepatol., 57, 1097, 10.1016/j.jhep.2012.04.041 Parés, 2004, Extracorporeal albumin dialysis: A procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis, Am J Gastroenterol., 99, 1105, 10.1111/j.1572-0241.2004.30204.x Leckie, 2012, ‘Out-patient’ albumin dialysis for cholestatic patients with intractable pruritus, Aliment Pharmacol Ther., 35, 696, 10.1111/j.1365-2036.2012.04994.x Singal, 2013, Evolving frequency and outcomes of liver transplantation based on etiology of liver disease, Transplantation., 95, 755, 10.1097/TP.0b013e31827afb3a Carbone, 2013, The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: A prospective study, J Hepatol., 59, 490, 10.1016/j.jhep.2013.04.017 Duclos-Vallee, 2009, Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation, Liver Transpl., 15, S25, 10.1002/lt.21916 Neuberger, 2004, Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation, Liver Transpl., 10, 488, 10.1002/lt.20123 Montano-Loza, 2019, Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival, Gastroenterology., 156, 96, 10.1053/j.gastro.2018.10.001 Eastell, 1991, Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis, Hepatology., 14, 296, 10.1002/hep.1840140215 Harms, 2019, Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis, J Hepatol., 71, 357, 10.1016/j.jhep.2019.04.001 Saffioti, 2017, Pharmacological interventions for primary biliary cholangitis: An attempted network meta-analysis, Chochrane Database Syst Rev., 3 Triantos, 2011, Meta-analysis: Ursodeoxycholic acid for primary sclerosing cholangitis, Aliment Pharmacol Ther., 34, 901, 10.1111/j.1365-2036.2011.04822.x